Unknown

Dataset Information

0

Structure-based discovery of highly selective phosphodiesterase-9A inhibitors and implications for inhibitor design.

ABSTRACT: A new series of phosphodiesterase-9 (PDE9) inhibitors that contain a scaffold of 6-amino-pyrazolopyrimidinone have been discovered by a combination of structure-based design and computational docking. This procedure significantly saved the load of chemical synthesis and is an effective method for the discovery of inhibitors. The best compound 28 has an IC(50) of 21 nM and 3.3 ?M, respectively, for PDE9 and PDE5 and about 3 orders of magnitude of selectivity against other PDE families. The crystal structure of the PDE9 catalytic domain in complex with 28 has been determined and shows a hydrogen bond between 28 and Tyr424. This hydrogen bond may account for the 860-fold selectivity of 28 against PDE1B, in comparison with about 30-fold selectivity of BAY73-6691. Thus, our studies suggest that Tyr424, a unique residue of PDE8 and PDE9, is a potential target for improvement of selectivity of PDE9 inhibitors.

SUBMITTER: Meng F 

PROVIDER: S-EPMC3469756 | biostudies-literature | 2012 Oct

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Structure-based discovery of highly selective phosphodiesterase-9A inhibitors and implications for inhibitor design.

Meng Fei F   Hou Jing J   Shao Yong-Xian YX   Wu Pei-Ying PY   Huang Manna M   Zhu Xinhai X   Cai Yonghong Y   Li Zhe Z   Xu Jie J   Liu Peiqing P   Luo Hai-Bin HB   Wan Yiqian Y   Ke Hengming H  

Journal of medicinal chemistry 20121001 19

A new series of phosphodiesterase-9 (PDE9) inhibitors that contain a scaffold of 6-amino-pyrazolopyrimidinone have been discovered by a combination of structure-based design and computational docking. This procedure significantly saved the load of chemical synthesis and is an effective method for the discovery of inhibitors. The best compound 28 has an IC(50) of 21 nM and 3.3 μM, respectively, for PDE9 and PDE5 and about 3 orders of magnitude of selectivity against other PDE families. The crysta  ...[more]

Similar Datasets

Unknown Discovery of a phosphodiesterase 9A inhibitor as a potential hypoglycemic agent.
| S-EPMC4281101 | biostudies-literature
Unknown Insight into binding of phosphodiesterase-9A selective inhibitors by crystal structures and mutagenesis.
| S-EPMC2831206 | biostudies-literature
Unknown Discovery of Novel and Highly Selective Cyclopropane ALK Inhibitors through a Fragment-Assisted, Structure-Based Drug Design.
| S-EPMC7745413 | biostudies-literature
Unknown Structure-Guided Design and Procognitive Assessment of a Potent and Selective Phosphodiesterase 2A Inhibitor.
| S-EPMC6088355 | biostudies-literature
Unknown Structural Asymmetry of Phosphodiesterase-9A and a Unique Pocket for Selective Binding of a Potent Enantiomeric Inhibitor.
| S-EPMC4613944 | biostudies-literature
Unknown Biological and structural characterization of Trypanosoma cruzi phosphodiesterase C and Implications for design of parasite selective inhibitors.
| S-EPMC3320927 | biostudies-literature
Unknown Structural basis for the design of selective phosphodiesterase 4B inhibitors.
| S-EPMC4057648 | biostudies-literature
Unknown First-in-human study assessing safety, tolerability and pharmacokinetics of BI 409306, a selective phosphodiesterase 9A inhibitor, in healthy males.
| S-EPMC5061793 | biostudies-literature
Unknown Crystal structure of the Leishmania major phosphodiesterase LmjPDEB1 and insight into the design of the parasite-selective inhibitors.
| S-EPMC2950065 | biostudies-literature
Unknown Design, synthesis, and structure-activity relationship, molecular modeling, and NMR studies of a series of phenyl alkyl ketones as highly potent and selective phosphodiesterase-4 inhibitors.
| S-EPMC2950628 | biostudies-literature